Overview

Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)

Status:
Not yet recruiting

Trial end date:
2022-11-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, 2-arm open-label, randomized comparative phase II study in each of two separate cohorts (non-squamous NSCLC and squamous NSCLC) according to histology.

Phase:

Phase 2

Details

Lead Sponsor:

European Organisation for Research and Treatment of Cancer - EORTC

Treatments:

Antibodies, Monoclonal
Durvalumab
Tremelimumab